Armata Pharmaceuticals Inc (ARMP) has disclosed a new risk, in the Costs category.
Armata Pharmaceuticals Inc. confronts significant business risk as governments and healthcare payors intensify efforts to curtail healthcare costs, potentially diminishing the company’s product revenues. The imposition of utilization management tools and preference for generics exacerbate the challenges in sustaining favorable pricing and formulary positions for Armata’s offerings. Moreover, legislative endeavors, such as changes to the Patient Protection and Affordable Care Act, inject further uncertainty into the market dynamics, threatening both domestic and international pricing structures and reimbursement levels, which could lead to increased pricing pressures and adverse effects on the company’s financial health.
Overall, Wall Street has a Moderate Buy consensus rating on ARMP stock based on 1 Buy.
To learn more about Armata Pharmaceuticals Inc’s risk factors, click here.
